Benzinga · Aug 24, 2026
Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target
Guggenheim analyst Vamil Divan reiterates Eloxx Pharma (NASDAQ:ELOX) with a Buy and maintains $43 price target.
OTC · ELOX
Eloxx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$15.75
Down-$0.53 (-3.26%)
Updated Sep 13, 2026, 2:03 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 314
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $23.40
- Volume
- 17.17K
- Avg. volume
- 1.44K
Price performance
ELOX price history
1M range · 19 trading sessions · Daily adjusted prices
ELOX closed at $15.75 after 19 trading sessions, down 14.73% for the selected period.
- Last close
- $15.75
- Period change
- -14.73%
- Period low
- $14.19
- Period high
- $20.98
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $16.74 | $17.19 | $15.00 | $15.75 | 17.17K |
| Sep 10, 2026 | $16.50 | $17.15 | $15.745 | $16.28 | 28.69K |
| Sep 9, 2026 | $16.03 | $17.74 | $15.16 | $16.57 | 37.44K |
| Sep 8, 2026 | $15.49 | $17.42 | $15.0001 | $16.17 | 29.18K |
| Sep 4, 2026 | $14.06 | $16.48 | $14.06 | $15.00 | 38.84K |
| Sep 3, 2026 | $15.98 | $16.975 | $13.79 | $14.19 | 37.46K |
| Sep 2, 2026 | $14.80 | $16.50 | $14.71 | $15.84 | 57.78K |
| Sep 1, 2026 | $16.81 | $16.81 | $15.01 | $15.01 | 34.08K |
| Aug 31, 2026 | $15.00 | $17.325 | $13.9327 | $16.77 | 38.9K |
| Aug 28, 2026 | $16.22 | $16.8038 | $15.07 | $15.07 | 32.11K |
| Aug 27, 2026 | $18.17 | $18.3632 | $15.0701 | $16.00 | 20.47K |
| Aug 26, 2026 | $19.11 | $19.82 | $16.4977 | $18.53 | 52.76K |
| Aug 25, 2026 | $19.84 | $19.84 | $18.01 | $19.29 | 33.94K |
| Aug 24, 2026 | $21.60 | $23.00 | $18.5795 | $19.99 | 151.56K |
| Aug 21, 2026 | $19.00 | $23.3999 | $18.04 | $20.975 | 93.39K |
| Aug 20, 2026 | $19.00 | $19.18 | $17.75 | $18.04 | 40.28K |
| Aug 19, 2026 | $17.56 | $19.00 | $16.90 | $18.155 | 62.74K |
| Aug 18, 2026 | $18.47 | $18.47 | $16.50 | $18.25 | 38.25K |
| Aug 17, 2026 | $18.87 | $18.90 | $17.735 | $18.47 | 27.93K |
Latest ELOX news
The latest Smart Investors Daily articles mentioning ELOX.
Stock researchCompany · Overview
ELOX research
Overview
Company profile and research snapshot.
Company profile
ELOXX PHARMACEUTICALS INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Guggenheim | Buy | — |
| Aug 20, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jul 22, 2026 | LifeSci Capital | Outperform | — |
| Jul 20, 2026 | Guggenheim | Buy | — |
| Jul 11, 2023 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 24, 2026
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings came out 3
Benzinga · Aug 20, 2026
LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.
Benzinga · Jul 22, 2026
LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40
LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
